三生製藥(01530.HK)分拆三生國健科創板上市申請獲上交所受理
格隆匯10月31日丨三生製藥(01530.HK)公佈,於2019年10月31日,上海證券交易所正式接受公司的間接非全資附屬公司三生國健的分拆申請,以於科創板上市。
董事認為,建議分拆將(i)量化三生國健股權的市場價格;(ii)為三生國健提供新的資金來源;(iii)提升該集團及分拆集團的企業及品牌知名度;(iv)提升企業管治;(v)吸引人才加入三生國健及提升三生國健的標準、能力及專業知識;及(vi)有助於三生國健及該集團更專注於發展其各自的業務及進行策略規劃。因此,董事會認為,建議分拆能為該集團帶來明顯的商業利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.